PIK3CA and neoplasm: As expected, the duligotuzumab and pictilisib combination was more effective than the cetuximab and pictilisib combination in the regression of tumor growth of HCC70 xenografts, since inhibition of EGFR, AKT, or PI3K induced the abundance of HER3 [474,475,476], which was inhibited by duligotuzumab but not by cetuximab.